Key result
Review compares chlorthalidone versus hydrochlorothiazide for reducing MACE in primary hypertension.
Why the study?
Although chlorthalidone is recommended over hydrochlorothiazide for primary hypertension due to greater MACE reduction, hydrochlorothiazide remains more commonly prescribed.
Does chlorthalidone reduce major adverse cardiovascular events compared to hydrochlorothiazide in patients with primary hypertension?
Does chlorthalidone reduce major adverse cardiovascular events compared to hydrochlorothiazide in patients with primary hypertension?
This review evaluates the comparative effectiveness of chlorthalidone versus hydrochlorothiazide in reducing MACE for patients with primary hypertension.
Answers are grounded in this paper and cite their sources.
May not yet alter thiazide choice in hypertension; leaves open need for definitive comparative trials.
Because of its greater reduction of major adverse cardiovascular events (MACE), chlorthalidone is recommended over hydrochlorothiazide as the preferred diuretic for patients with primary hypertension. However, hydrochlorothiazide is more commonly prescribed than chlorthalidone for this condition. This article reviews recent studies investigating the effectiveness of chlorthalidone and hydrochlorothiazide in reducing MACE, to help clinicians make an evidence-based informed decision on which diuretic to prescribe.
No takes yet. Share an insight, caveat, or question.
T Young (2024) conducted a review in primary hypertension. chlorthalidone vs. hydrochlorothiazide was evaluated on major adverse cardiovascular events (MACE). This review evaluates recent studies comparing the effectiveness of chlorthalidone versus hydrochlorothiazide in reducing major adverse cardiovascular events in patients with primary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: